Clinical Trial Update: AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial DURGA-1 evaluating AZD0120 in relapsed/refractory multiple myeloma is in Phase 1/Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZD0120

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING